Native functionality and therapeutic targeting of arenaviral glycoproteins  by Crispin, Max et al.
Native functionality and therapeutic targeting of
arenaviral glycoproteins
Max Crispin1, Antra Zeltina2, Nicole Zitzmann1 and
Thomas A Bowden2
Available online at www.sciencedirect.com
ScienceDirectSurface glycoproteins direct cellular targeting, attachment, and
membrane fusion of arenaviruses and are the primary target for
neutralizing antibodies. Despite significant conservation of the
glycoprotein architecture across the arenavirus family, there is
considerable variation in the molecular recognition
mechanisms used during host cell entry. We review recent
progress in dissecting these infection events and describe how
arenaviral glycoproteins can be targeted by small-molecule
antivirals, the natural immune response, and immunoglobulin-
based therapeutics. Arenaviral glycoprotein-mediated
assembly and infection pathways present numerous
opportunities and challenges for therapeutic intervention.
Addresses
1Oxford Glycobiology Institute, Department of Biochemistry, University
of Oxford, South Parks Road, Oxford OX1 3QU, UK
2Division of Structural Biology, Wellcome Trust Centre for Human
Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
Corresponding authors: Crispin, Max (max.crispin@bioch.ox.ac.uk) and
Bowden, Thomas A (thomas.bowden@strubi.ox.ac.uk)
Current Opinion in Virology 2016, 18:70–75
This review comes from a themed issue on Virus structure and
expression
Edited by Adam Zlotnick and Juha T Huiskonen
For a complete overview see the Issue and the Editorial
Available online 19th April 2016
http://dx.doi.org/10.1016/j.coviro.2016.04.001
1879-6257/# 2016 The Authors. Published by Elsevier B.V. This is an
open access article under the CC BY license (http://creativecom-
mons.org/licenses/by/4.0/).
Introduction
Pathogenic arenaviruses from the Arenaviridae family can
cause a range of human diseases, including severe hemor-
rhagic fever and fatal transplant-associated infection [1].
Whilst good medical practice [2] and community hygiene
[3,4] can limit viral transmission, arenaviruses are under
increasing scrutiny due to their categorization as biosecurity
risks. Our increasing knowledge of arenavirus structure and
pathobiology provides a detailed molecular picture of key
events during viral zoonosis and immune resolution of infec-
tion. Here, we describe these recent advances and discuss the
challenges and opportunities of targeting arenaviruses at that
initial stage of host cell entry and viral biogenesis.
Mammalian arenaviruses are predominantly found in the
Americas and Africa and are consequently commonlyCurrent Opinion in Virology 2016, 18:70–75 classified as either New or Old World, respectively. While
currently no clade distinctions are made amongst the Old
World arenaviruses, New World arenaviruses are divided
into four clades (A–D) [5]. Mammalian New and Old
World arenaviruses reside in a range of rodent species and
transmission of these viruses to humans is often associat-
ed with perturbation of natural habitats. For example, the
causative agent for Bolivian hemorrhagic fever was
termed Machupo virus (MACV) after an outbreak in the
community around the Machupo river, where it is believed
mice had been attracted by expanding agriculture.
Although rodents are the most significant host reservoir,
arenaviruses have also been identified in reptiles. Viruses
belonging to the newgenus Reptarenavirus within the family
Arenaviridae, are believed to be the etiological agents of the
fatal inclusion body disease in alethinophidian snakes
[5,7,8,9], but their role in human disease, if any, has
not been established. Given the diverse nature of these
animal reservoirs, it is likely that further host species will be
identified.
The arenavirus genome is ambi-sense and consists of two
separate segments of RNA, termed L and S. The L
segment encodes the RNA-dependent polymerase
(L protein) and zinc-binding matrix protein (Z protein)
whereas the S segment encodes the nucleoprotein and
the glycoprotein precursor (GPC). During the viral gly-
coprotein maturation, GPC is cleaved into three compo-
nents; a stable signal peptide (SSP) of an unusual length
that is retained as an essential component of the mature
complex, an attachment glycoprotein (GP1) and fusion
glycoprotein (GP2) [10]. Low resolution electron cryo-
microscopy combined with sub-tomogram averaging has
revealed that these three components associate to form a
three-legged trimeric spike, measuring 9 nm in height
and 10 nm in width (Figure 1), which undergoes pH-
dependent conformational changes [11].
Structure of the arenaviral GP1 attachment
glycoprotein
Crystal structures have been determined for the GP1
attachment glycoproteins of Old World Lassa virus
(LASV) [12] and the New World arenaviruses, MACV
[13] and Junı´n virus (JUNV) [14] (Figure 2). Despite
low sequence conservation between these viral glycopro-
teins, all three structures display a highly similar compact
a/b fold. The domain consists of a twisted b-sheet, which
is surrounded by an array of a-helices. The N-linkedwww.sciencedirect.com
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Cryo-EM analysis of LASV reveals the higher order architecture and
receptor-binding properties of the Old World arenavirus SSP–GP1–
GP2 spike complex. Schematic of the 14 A˚-resolution structure of the
LASV glycoprotein spike in complex with LAMP receptor at pH 5.0
(EMD accession code EMD-3293). Density corresponding to the GP1–
GP2 complex is coloured blue, human LAMP1 is green, and the lipid
bilayer is grey.glycosylation sites cluster around the perimeter of the
fold, although bioinformatics analysis revealed that they
display only limited conservation in absolute position
across the family [13]. The most significant conformation-
al difference between the New World and LASV GP1
structures is the re-positioning of the termini [12]. This
has been attributed to a pH-induced conformational
change, reflecting the different pH conditions used for
crystallization. This hypothesis is consistent with the
conformational change that LASV GP1 has been pro-
posed to undergo upon entry into endosomal compart-
ments of the host cell [15]. Nevertheless, this remains toFigure 2
(a)
MACV GP1 JUNV
New World
Comparison of New and Old World arenaviral GP1 attachment glycoprotein
2WFO, left) and JUNV (PDB accession code 5EN2, right) GP1 glycoproteins
accession code 4ZJF). Structures are shown in cartoon representation and 
terminus and C-terminus are shown as blue and red spheres, respectively.
www.sciencedirect.com be systematically tested to exclude the effect of primary
sequence divergence between the glycoproteins and oth-
er experimental factors such as crystal lattice effects.
Attachment of New World arenaviruses at the
host-cell surface
New and Old World arenaviruses utilize different recep-
tors. The hemorrhagic New World clade B JUNV,
MACV, Guanarito (GTOV), Sabia (SABV) and Chapare
(CHPV) viruses, as well as the apathogenic arenaviruses
of the same clade, use transferrin receptor 1 (TfR1) for
cell entry into their natural rodent hosts [16,17]. Patho-
genic arenaviruses display protein recognition modes by
GP1 that lead to cross-reactivity with human TfR1,
providing a rationale for viral zoonosis into human popu-
lations. This phenomenon is also observed in North
American clade D (formerly known as clade A/B or A/
rec) [5] viruses. These viruses also utilize TfR1 orthologs
of their respective natural rodent hosts, with one member
of the Whitewater Arroyo species complex showing addi-
tional ability to utilize human TfR1 [18]. Furthermore,
although North American arenaviruses are generally con-
sidered non-pathogenic, Whitewater Arroyo virus has
been tentatively implicated in the death of three people
in California [19].
Structural analysis of MACV GP1 in complex with human
TfR1 provides a molecular rationale for observed spill
over of New World arenaviruses into human populations
[20–22] (Figure 3a). MACV GP1 binds to the apical
domain of TfR1, at a site not used by either of the
physiological ligands transferrin and hereditary hemo-
chromostasis associated protein. Interestingly, it has been
suggested antibodies that target TfR1 apical domain may
have antiviral potential [23]. However, it is important to
note that parameters beyond receptor specificity alone
may dictate effective zoonosis. In one extreme example, a GP1 LASV GP1
Old World
(b)
Current Opinion in Virology
 folds. (a) Crystal structures of New World MACV (PDB accession code
. (b) Crystal structure of Old World LASV GP1 glycoprotein (PDB
ramped from blue at the N-terminus to red at the C-terminus. The N-
Current Opinion in Virology 2016, 18:70–75
72 Virus structure and expression
Figure 3
(a)
MACV
GP1 apical helical
protease-like
TfR1
Heavy
Chain
MACV
GP1
JUNV
GP1
Light
Chain
(b)
Current Opinion in Virology
Crystal structures of receptor-bound and antibody-bound New World arenavirus GP1 complexes. (a) Crystal structure of MACV GP1 bound to the
TfR1 ectodomain (PDB accession code 3KAS). The TfR1 homodimer is shown as a cartoon with a transparent van der Waals surface. One
protomer of the dimer is coloured according to domain (apical domain coloured green, protease-like domain coloured orange, and helical domain
coloured blue) and the other white. MACV GP1 is coloured as in Figure 2. (b) Crystal structure of JUNV GP1 bound to the Fab of a neutralizing
monoclonal antibody derived from a mouse (PDB accession code 5EN2). The Fab heterodimer is shown as a cartoon with a surrounding van der
Waals surface. The heavy chain of the Fab is coloured pink and the light chain coloured blue. JUNV GP1 is coloured as in Figure 2.recent study on reptarenavirus propagation in cell cul-
ture demonstrated ready infection of University of Hel-
sinki virus in human cells although this was only
efficient at 30 8C and was significantly impeded at
mammalian body temperature [24]. Another example
is the finding that all known human-pathogenic arena-
viruses, but not non-pathogenic arenaviruses, share a
Z-protein-mediated innate immune suppression mech-
anism that blunts the interferon-mediated antiviral
responses [25]. These observations underscore that
whilst arenavirus–cell surface interactions are necessary
for infection, these conditions alone may not be suffi-
cient to establish infection.
Old World arenavirus attachment factors
No Old World arenaviruses are known to utilize the
TfR1-mediated host-cell entry pathway. Instead, Old
World arenaviruses such as LASV, lymphocytic chorio-
meningitis virus (LCMV), Mobala, as well as clade C
New World viruses Oliveros and Latino, have been
shown to functionally recognize the a subunit of dys-
troglycan (a-dystroglycan) [26–31]. Dystroglycan is
widely expressed and is integral in linking the extracel-
lular matrix to the cytoskeleton [32,33]. Interestingly,
LASV recognition is dependent on the structure of the
conjugated O-glycans displayed on a-dystroglycan. This
leads to a dependency for O-glycan biosynthesis factors
such as the transferase LARGE, which is important in
elaborating O-mannosyl initiated glycans on a-dystro-
glycan [30,34,35]. In addition to these entry mecha-
nisms, lectin-mediated and other protein-mediated
pathways may contribute to LASV infection of certain
cell types [36].Current Opinion in Virology 2016, 18:70–75 During endocytosis and exposure to the acidic interior of
late endosomes (pH 5–5.5), LASV binds to lysosomal
associated membrane protein 1 (LAMP-1) [15] at the tip
of the viral spike (Figure 1) [11]. This pH-dependent
interaction [15] is controlled by a histidine-switch at the
putative binding face of LASV GP1 [12] and is depen-
dent on both a2,3-linked sialylation and the presence of a
single N-linked glycan on LAMP-1 [15]. Although the
molecular bases for LASV GP1-dystroglycan and GP1–
LAMP-1 interactions are yet to be elucidated, the shared
dependency on glycans for both complexes is suggestive
of related modes of interaction. Immunologically, Jae
et al. make the interesting observation that the upper
and lower human respiratory tract is dominated by a2,6-
linked and a2,3-lined sialylated glycans, respectively,
which may impede LASV infection [15].
LAMP-1 dependency does not appear to be shared across
Old World arenaviruses and, for example, is not required
for LCMV infection [15]. The variable dependency on
the lysosomal factors would seem to suggest that we have
an incomplete picture of this critical stage of the infection
cycle.
Viral membrane fusion with the host
Following arenaviral endocytosis, the GP1 is shed and
membrane fusion is mediated by GP2. It is suggested that
GP1 may act as a molecular shield preventing premature
conformational changes [11]. Whilst pre-fusion crystal
structures of the GP2 have yet to be determined, the
structures of LCMV and GTOV GP2 in their post-fusion
conformation reveal a well-conserved, class I fusion pro-
tein architecture common to a number of envelopedwww.sciencedirect.com
Structure and targeting of arenaviral glycoproteins Crispin et al. 73viruses such as the Orthomyxoviridae, Filoviridae, and
Paramyxoviridae [37,38]. Class I fusion glycoproteins
exhibit an a-helical architecture and form an extended
coiled-coil structure upon fusion. Upon cleavage of
the GPC, the GP2 is rendered metastable and exposure
to endosomal pH drives consequent rearrangements
and membrane merger [10]. Interestingly,  small mole-
cule inhibitors of arenavirus cell entry are believed to
target the pH-sensitive molecular interface between
SSP and GP2, resulting in inhibition of pH-induced
fusion [10,39].
Arenaviral glycoproteins are targeted by
neutralizing antibodies
The high mortality rate arising from infection by some
arenaviruses, such as 15–30% mortality in JUNV infec-
tion, indicates that the human immune system can fail to
control infection [40]. However, passive transfer of immu-
noglobulins from convalescent patients is an effective
treatment for acute human JUNV infections [41–43].
The molecular basis for viral neutralization has elegantly
been revealed through the elucidation of the crystal
structure of the JUNV GP1 in complex with a neutralizing
IgG2a Fab [14] (Figure 3b). The originating antibody
was raised in mice by immunization with inactivated
JUNV [44]. The antibody achieves neutralization through
the recognition of the TfR1 binding interface. The inter-
action mimics a central GP1-receptor contact by inserting
a tyrosine residue into a pocket on the GP1. Thus,
neutralization is most probably achieved by interfering
with binding to the host cell receptor. Consistent with this
hypothesis, Mahmutovic et al. demonstrate that the re-
ceptor binding site is also a targeted by antibodies con-
tained in the polyclonal immunoglobulin pool of JUNV
survivors [14]. Given the practical limitations of conva-
lescent serum therapy [41], the GP1–TfR1 interface
provides a promising target for rational development of
alternative antibody and small-molecule antivirals [45].
An example of promising antibody therapy is a glycopro-
tein-specific IgG cocktail, produced by DNA vaccination,
that has been demonstrated to protect experimental
animals against lethal JUNV and GTOV challenge
[46]. Encouragingly, some, albeit limited, cross-neutrali-
zation was observed between the JUNV and MACV
glycoprotein-specific sera [46].
Prospects for arenaviral vaccines
Although cell-mediated immunity is likely to play an
important role, the ready neutralization of JUNV by
antibodies is consistent with the development of the only
currently available arenavirus vaccine Candid#1, which is
composed of live-attenuated JUNV and is licensed in
Argentina for the vaccination of populations within high-
risk areas [47]. The successful development of a JUNV
vaccine has stimulated considerable interest in the de-
velopment of vaccines to other arenaviruses and poten-
tially cross-protective vaccines [46,48–51].www.sciencedirect.com The success in vaccine development and the efficacy of
survivor plasma transfusion in the treatment of JUNV-
mediated hemorrhagic fever has, however, not been
mirrored in LASV vaccinology [52,53]. Delayed and weak
neutralizing antibody responses have been observed both
in natural infection [54] and in candidate vaccine trials
[55,56]. Interestingly, the higher glycan density on the
LASV GP1 compared to JUNV GP1 does seem to shield
the LASV envelope against efficient antibody-mediated
neutralization [57]. Despite these observations, the dis-
covery of antibodies that can bind to and penetrate the
glycan shield of the attachment glycoprotein of the hu-
man immunodeficiency virus gives hope that these glycan
effects are not insurmountable [58–60]. Nevertheless, it is
currently uncertain whether successful arenaviral vac-
cines will be dependent on potent antibodies or whether
they will rely predominantly on a strong cellular compo-
nent.
Antivirals targeting glycoprotein folding
Although ribavirin has been found somewhat effective for
the treatment of hemorrhagic fevers caused by arena-
viruses such as LASV and JUNV [61], there are currently
no virus-specific small-molecule antiviral agents ap-
proved for the treatment of arenaviruses. However, are-
naviruses have been shown to be vulnerable to drugs that
target viral glycoprotein folding by inhibiting host cell ER
a-glucosidases, such as iminosugars. These small mole-
cule drugs have demonstrated in vitro efficacy against
Pichinde virus, JUNV, and Tacaribe virus [62]. The
initial success of these compounds highlights the differ-
ential dependency of the glycan-mediated folding path-
way between self and viral glycoprotein biosynthesis and
suggests a promising window for therapeutic control of
infection.
Perspectives
Recent structural analyses of arenavirus glycoproteins,
alone and in complex with receptors and antibodies, have
revealed that these surface-exposed molecules are both
key determinants of species tropism and clear targets for
therapeutic intervention. We anticipate that further struc-
tural and mechanistic studies will further help to define
features of the arenaviral life cycle that can be targeted in
next generation cross-protective vaccines and therapies.
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